Biopharmaceutical company developing glycomimetic drugs for treating diseases.
GlycoMimetics, Inc., a clinical-stage biotechnology firm, specializes in discovering and developing novel glycomimetic drugs to address unmet medical needs in the United States. The company's lead product, uproleselan, is an E-selectin inhibitor used in combination with chemotherapy for treating acute myeloid leukemia (AML). Uproleselan is currently in a Phase 3 trial targeting relapsed/refractory AML, demonstrating its potential in enhancing chemotherapy efficacy.
Additionally, GlycoMimetics is advancing GMI-1359, a dual inhibitor targeting E-selectin and a chemokine receptor, aimed at treating cancers affecting the bone and bone marrow, including solid tumors. The company's pipeline includes various other programs, such as GMI-1687, an E-selectin antagonist for vaso-occlusive crisis treatment, and galectin-3 antagonists, targeting a carbohydrate-binding protein involved in numerous pathological processes.
Headquartered in Rockville, Maryland, GlycoMimetics was incorporated in 2003 and has established significant partnerships to bolster its research and development efforts. The company collaborates with the National Cancer Institute and has a strategic agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687, reinforcing its commitment to advancing therapeutic options for challenging diseases.